HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment
C Eggers, G Arendt, K Hahn, IW Husstedt… - Journal of …, 2017 - Springer
The modern antiretroviral treatment of human immunodeficiency virus (HIV-1) infection has
considerably lowered the incidence of opportunistic infections. With the exception of the …
considerably lowered the incidence of opportunistic infections. With the exception of the …
Human immunodeficiency virus‐associated neurocognitive disorders: mind the gap
JC McArthur, J Steiner, N Sacktor, A Nath - Annals of neurology, 2010 - Wiley Online Library
Human immunodeficiency virus (HIV)‐associated neurocognitive disorders (HANDs) remain
among the most common disorders in people infected with HIV, even in an era when potent …
among the most common disorders in people infected with HIV, even in an era when potent …
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
Objectives: This is a cross-sectional, observational study to determine the frequency and
associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse …
associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse …
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline
Objective: While HIV-associated neurocognitive disorders (HAND) remain prevalent despite
combination antiretroviral therapy (CART), the clinical relevance of asymptomatic …
combination antiretroviral therapy (CART), the clinical relevance of asymptomatic …
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities
KA Lindl, DR Marks, DL Kolson… - Journal of neuroimmune …, 2010 - Springer
Human immunodeficiency virus type 1 (HIV) infection presently affects more that 40 million
people worldwide, and is associated with central nervous system (CNS) disruption in at least …
people worldwide, and is associated with central nervous system (CNS) disruption in at least …
Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection
Objective: Mild forms of HIV-associated neurocognitive disorders (HAND) remain prevalent
in the era of combination antiretroviral therapy (cART). Although elevated …
in the era of combination antiretroviral therapy (cART). Although elevated …
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort
KR Robertson, Z Su, DM Margolis, A Krambrink… - Neurology, 2010 - AAN Enterprises
Objective: Prior studies have shown improved neurocognition with initiation of antiretroviral
treatment (ART) in HIV. We hypothesized that stopping ART would be associated with …
treatment (ART) in HIV. We hypothesized that stopping ART would be associated with …
Clinical factors related to brain structure in HIV: the CHARTER study
TL Jernigan, SL Archibald, C Fennema-Notestine… - Journal of …, 2011 - Springer
Despite the widening use of combination antiretroviral therapy (ART), neurocognitive
impairment remains common among HIV-infected (HIV+) individuals. Associations between …
impairment remains common among HIV-infected (HIV+) individuals. Associations between …
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management
People living with HIV are affected by the chronic consequences of neurocognitive
impairment (NCI) despite antiretroviral therapies that suppress viral replication, improve …
impairment (NCI) despite antiretroviral therapies that suppress viral replication, improve …
HIV-associated neurocognitive disorder
RC Smail, BJ Brew - Handbook of clinical neurology, 2018 - Elsevier
Human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) affects
roughly half the HIV-positive population. The symptoms of cognitive slowing, poor …
roughly half the HIV-positive population. The symptoms of cognitive slowing, poor …